SUPPLEMENTARY FIGURES

Supplementary Figure 1. Safety of Glycitin in vitro and in vivo. (A) The hNP cells were cultured and treated with Glycitin between 24h, 48h and 72 h. Cell viability was measured using the CCK8 assay in hNP cells. (B) The heart, liver, lung, and kidney were isolated from rat treated with Glycitin for 4 weeks. (Scale bar = 500 µm). All data are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p <0.001, ****p < 0.0001 versus control group.

Supplementary Figure 2. Glycitin mimics the role of SN50 in inhibition of the NF-κB signalling pathway. (A–D) HNPCs were treated with DMSO, TNF-α (10 ng/ml), TNF-α (10 ng/ml) + SN50 (15 µM) and TNF-α (10 ng/ml) + Glycitin (100 µg/ml) 48 hours. Aggrecan, COX-2, ADAMTs-5 were tested by Western blot. The expression of proteins mentioned above were quantitatively analyzed related to GAPDH (n=3). (E, F) HNPCs were treated with DMSO, TNF-α (10 ng/ml), TNF-α (10 ng/ml) + SN50 (15 µM) and TNF-α (10 ng/ml) + Glycitin (100 µg/ml) for 24 hours. Western blot shows the expression of p-P65 and p65. The expression of proteins mentioned above was quantitatively analyzed (n=3). All data are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p <0.001, ****p < 0.0001 versus control group.